

Appl. No. : 09/632,074
Filed : August 2, 2000

60% similarity thereto while retaining leptin activity or antagonist activity as well as a molecule encoded by the nucleotide sequence set forth in (SEQ ID NO:1) or a nucleotide sequence having at least about 60% similarity thereto or a nucleotide sequence capable of hybridising to (SEQ ID NO:1) under low stringency conditions at 42°C.

On page 19, please remove Table 4 and replace it with the following Table 4: --

Gene	Forward Primer	Backward Primer	Product Size
GAPDH	5=CAGTCAGCCGCATCTTCTTTT 3= (SEQ ID NO:3)	5=TGGTTCACACCCATGACGAAC 3= (SEQ ID NO:4)	464bp
OPG	5=GTACGTCAAGCAGGAGTGCAATC 3= (SEQ ID NO:5)	5=TTCTTGAGCTGTGTGCGC 3= (SEQ ID NO:6)	472 bp
RANK	5=TTAAGCCAGTGCTTCACGGG 3= (SEQ ID NO:7)	5=ACGTAGACCACGATGATGTCGC 3= (SEQ ID NO:8)	497 bp

IN THE SEQUENCE LISTING:

Please cancel the original sequence listing, pages i-vi and insert the attached Replacement Sequence Listing pages 1-4.

REMARKS

The amendments made herein conform the application to practice in the United States Patent and Trademark Office. This response to Notice to Comply conforms the sequence listing to the rules of practice specified by the U.S. Patent and Trademark Office. Enclosed herewith are (1) a paper copy of the Replacement Sequence Listing, and (2) a computer readable copy of the Replacement Sequence Listing.

The changes made to the claims by the current amendment, including **[deletions]** and **additions**, are shown on an attached sheet entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment.

VERIFICATION UNDER 37 C.F.R. §1.821(f) & (g)

The polypeptide sequence appearing in the attached Sequence Listing was included in the application as filed. Pursuant to 37 C.F.R. §1.821(g), no new matter is being added herewith. As required under 37 C.F.R. §1.821(f), I hereby verify that the data on the enclosed disk and the paper copies of the Sequence Listing are identical.